AVITA Medical to Host Investor Webinar Briefing
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.
The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.
Positive
- None.
Negative
- None.
News Market Reaction – RCEL
On the day this news was published, RCEL gained 13.18%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.9% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $130M at that time.
Data tracked by StockTitan Argus on the day of publication.
VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time).
The webinar presentation will cover financial and business results from our recent second-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
Register: https://us06web.zoom.us/webinar/register/WN_LkikThGHT0yE-xWNoH6bRw
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burns and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical's (RCEL) Q2 2025 investor webinar?
Who will present at AVITA Medical's investor webinar?
How can investors participate in AVITA Medical's Q2 2025 webinar?
Where can I watch the replay of AVITA Medical's investor presentation?
